A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)
PHASE3CompletedINTERVENTIONAL
Enrollment
160
Participants
Timeline
Start Date
November 30, 1986
Primary Completion Date
June 30, 1994
Conditions
Leukemia
Interventions
BIOLOGICAL
sargramostim
DRUG
amsacrine
DRUG
cytarabine
DRUG
daunorubicin hydrochloride
PROCEDURE
quality-of-life assessment
All Listed Sponsors
lead
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
NCT01324063 - A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B) | Biotech Hunter | Biotech Hunter